Keefer, Laurel A.
White, James R. http://orcid.org/0000-0002-7535-9179
Wood, Derrick E. http://orcid.org/0000-0002-7429-1854
Gerding, Kelly M. R.
Valkenburg, Kenneth C.
Riley, David
Gault, Christopher
Papp, Eniko
Vollmer, Christine M.
Greer, Amy
Hernandez, James
McGregor, Paul M. III
Zingone, Adriana http://orcid.org/0000-0003-3747-937X
Ryan, Bríd M. http://orcid.org/0000-0003-0038-131X
Deak, Kristen http://orcid.org/0000-0002-5000-6326
McCall, Shannon J. http://orcid.org/0000-0003-3957-061X
Datto, Michael B.
Prescott, James L.
Thompson, John F. http://orcid.org/0000-0001-8568-3311
Cerqueira, Gustavo C.
Jones, Siân
Simmons, John K.
McElhinny, Abigail
Dickey, Jennifer
Angiuoli, Samuel V.
Diaz, Luis A. Jr.
Velculescu, Victor E.
Sausen, Mark http://orcid.org/0000-0002-2916-5269
Article History
Received: 26 January 2021
Accepted: 27 April 2022
First Online: 20 May 2022
Competing interests
: J.R.W. is the founder and owner of Resphera Biosciences LLC and serves as a consultant to Personal Genome Diagnostics. K.M.R.G., K.C.V., D.R., C.G., A.G., P.M.M., J.D., S.V.A., and M.S. are employees of Personal Genome Diagnostics. J.L.P. is an employee and stockholder of PathGroup. L.D. is a member of the board of directors of Jounce Therapeutics and Epitope. He is a compensated consultant to PetDx, Innovatus CP, Se’er, Delfi, Kinnate and Neophore. He is an inventor of multiple licensed patents (to Qiagen, Exact Biosciences, and LabCorp) related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy. Some of these licenses and relationships are associated with equity or royalty payments to the inventors. He holds equity in Epitope, Jounce Therapeutics, PetDx, Se’er, Delfi, Kinnate and Neophore. He divested his equity in Personal Genome Diagnostics to LabCorp in February 2022 and divested his equity in Thrive Earlier Detection to Exact Biosciences in January 2021. His spouse holds equity in Amgen. The terms of all these arrangements are being managed by Memorial Sloan Kettering in accordance with their conflict-of-interest policy. V.E.V. is a founder of Delfi Diagnostics, serves on the Board of Directors and as a consultant for this organization, and owns Delfi Diagnostics stock, which is subject to certain restrictions under university policy. Additionally, Johns Hopkins University owns equity in Delfi Diagnostics. V.E.V. divested his equity in Personal Genome Diagnostics to LabCorp in February 2022. V.E.V. is an inventor on patent applications submitted by Johns Hopkins University related to cancer genomic analyses and cell-free DNA for cancer detection that have been licensed to one or more entities, including Delfi Diagnostics, LabCorp, Qiagen, Sysmex, Agios, Genzyme, Esoterix, Ventana and ManaT Bio. Under the terms of these license agreements, the University and inventors are entitled to fees and royalty distributions. V.E.V. is an advisor to Danaher, Takeda Pharmaceuticals, and Viron Therapeutics. These arrangements have been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies. The remaining authors declare no competing interests.